Perspectives in the vaccine development against Opisthorchis viverrini liver fluke
Abstract Liver flukes, Opisthorchis viverrini, infect around 10 million individuals in Southeast Asia, alone, and cause 26,000 deaths in the region per year. Despite being classified as a Group 1 carcinogen, and presenting one of the leading causes of cholangiocarcinoma in epidemic areas, O. viverri...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-09-01
|
| Series: | MedComm – Biomaterials and Applications |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mba2.21 |
| _version_ | 1811166462270767104 |
|---|---|
| author | Ahmed O. Shalash Mariusz Skwarczynski Istvan Toth |
| author_facet | Ahmed O. Shalash Mariusz Skwarczynski Istvan Toth |
| author_sort | Ahmed O. Shalash |
| collection | DOAJ |
| description | Abstract Liver flukes, Opisthorchis viverrini, infect around 10 million individuals in Southeast Asia, alone, and cause 26,000 deaths in the region per year. Despite being classified as a Group 1 carcinogen, and presenting one of the leading causes of cholangiocarcinoma in epidemic areas, O. viverrini infection is a neglected tropical disease. Control measures were implemented in epidemic areas to limit the outspread of infection; however, prophylactic vaccines are urgently needed to protect against future reinfections. This holds especially true due to the limited curative efficacy of the approved anthelmintic drug. In this article, we have briefly summarized the recently reported information regarding hepatobiliary cancer pathogenesis, approved treatment, and control measures against infection. Further, we highlighted the progress in the identification of protective antigens against Opisthorchiasis and proposed the investigation of additional promising antigens relying on vaccine progress against related infectious parasites. We highlighted the relative efficacies of the developed preclinical vaccines, suggested alternative vaccine designs and combinations, and commented on the required immunological responses. Moreover, we also reviewed biomaterials used in vaccine delivery against O. viverrini infections, summarized all the reported vaccine design approaches against the disease, and provided future perspectives regarding vaccine development, the utilization of biomaterials, and the discovery of highly protective antigens. |
| first_indexed | 2024-04-10T15:52:50Z |
| format | Article |
| id | doaj.art-70d58db66fc4496298ec3c14f4ff05a2 |
| institution | Directory Open Access Journal |
| issn | 2769-643X |
| language | English |
| last_indexed | 2024-04-10T15:52:50Z |
| publishDate | 2022-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm – Biomaterials and Applications |
| spelling | doaj.art-70d58db66fc4496298ec3c14f4ff05a22023-02-10T23:20:05ZengWileyMedComm – Biomaterials and Applications2769-643X2022-09-0112n/an/a10.1002/mba2.21Perspectives in the vaccine development against Opisthorchis viverrini liver flukeAhmed O. Shalash0Mariusz Skwarczynski1Istvan Toth2School of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD AustraliaSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD AustraliaSchool of Chemistry and Molecular Biosciences The University of Queensland St Lucia QLD AustraliaAbstract Liver flukes, Opisthorchis viverrini, infect around 10 million individuals in Southeast Asia, alone, and cause 26,000 deaths in the region per year. Despite being classified as a Group 1 carcinogen, and presenting one of the leading causes of cholangiocarcinoma in epidemic areas, O. viverrini infection is a neglected tropical disease. Control measures were implemented in epidemic areas to limit the outspread of infection; however, prophylactic vaccines are urgently needed to protect against future reinfections. This holds especially true due to the limited curative efficacy of the approved anthelmintic drug. In this article, we have briefly summarized the recently reported information regarding hepatobiliary cancer pathogenesis, approved treatment, and control measures against infection. Further, we highlighted the progress in the identification of protective antigens against Opisthorchiasis and proposed the investigation of additional promising antigens relying on vaccine progress against related infectious parasites. We highlighted the relative efficacies of the developed preclinical vaccines, suggested alternative vaccine designs and combinations, and commented on the required immunological responses. Moreover, we also reviewed biomaterials used in vaccine delivery against O. viverrini infections, summarized all the reported vaccine design approaches against the disease, and provided future perspectives regarding vaccine development, the utilization of biomaterials, and the discovery of highly protective antigens.https://doi.org/10.1002/mba2.21cholangiocarcinomaextracellular vesiclesgranulin‐1Opisthorchis viverrinitetraspaninsvaccine |
| spellingShingle | Ahmed O. Shalash Mariusz Skwarczynski Istvan Toth Perspectives in the vaccine development against Opisthorchis viverrini liver fluke MedComm – Biomaterials and Applications cholangiocarcinoma extracellular vesicles granulin‐1 Opisthorchis viverrini tetraspanins vaccine |
| title | Perspectives in the vaccine development against Opisthorchis viverrini liver fluke |
| title_full | Perspectives in the vaccine development against Opisthorchis viverrini liver fluke |
| title_fullStr | Perspectives in the vaccine development against Opisthorchis viverrini liver fluke |
| title_full_unstemmed | Perspectives in the vaccine development against Opisthorchis viverrini liver fluke |
| title_short | Perspectives in the vaccine development against Opisthorchis viverrini liver fluke |
| title_sort | perspectives in the vaccine development against opisthorchis viverrini liver fluke |
| topic | cholangiocarcinoma extracellular vesicles granulin‐1 Opisthorchis viverrini tetraspanins vaccine |
| url | https://doi.org/10.1002/mba2.21 |
| work_keys_str_mv | AT ahmedoshalash perspectivesinthevaccinedevelopmentagainstopisthorchisviverriniliverfluke AT mariuszskwarczynski perspectivesinthevaccinedevelopmentagainstopisthorchisviverriniliverfluke AT istvantoth perspectivesinthevaccinedevelopmentagainstopisthorchisviverriniliverfluke |